L Gedda

Summary

Affiliation: Uppsala University
Country: Sweden

Publications

  1. ncbi Nuclisome--targeting the tumor cell nucleus
    Lars Gedda
    Department of Radiology, Oncology and Radiation Sciences, Unit of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, 751 85 Uppsala, Sweden
    Tumour Biol 33:661-7. 2012
  2. ncbi Experimental radionuclide therapy of HER2-expressing xenografts using two-step targeting nuclisome particles
    Lars Gedda
    Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    J Nucl Med 53:480-7. 2012
  3. ncbi Cytotoxicity and subcellular localization of boronated phenanthridinium analogues
    L Gedda
    Department of Diagnostic Radiology, Uppsala University, Sweden
    Anticancer Drug Des 12:671-85. 1997
  4. ncbi Real-time immunohistochemistry analysis of embedded tissue
    Lars Gedda
    Unit of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, SE 751 85 Uppsala, Sweden
    Appl Radiat Isot 68:2372-6. 2010
  5. ncbi The influence of lipophilicity on binding of boronated DNA-intercalating compounds in human glioma spheroids
    L Gedda
    Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Sweden
    Anticancer Drug Des 15:277-86. 2000
  6. ncbi Closo-dodecaborate(2-) as a linker for iodination of macromolecules. Aspects on conjugation chemistry and biodistribution
    V Tolmachev
    Division of Biomedical Radiation Sciences, Box 535, S 751 21, Uppsala University, Uppsala, Sweden
    Bioconjug Chem 10:338-45. 1999
  7. ncbi Conjugate chemistry and cellular processing of EGF-dextran
    J Carlsson
    Unit of Biomedical Radiation Sciences, Uppsala University, Sweden
    Acta Oncol 38:313-21. 1999
  8. ncbi Development and in vitro studies of epidermal growth factor-dextran conjugates for boron neutron capture therapy
    L Gedda
    Department of Diagnostic Radiology, Uppsala University, Sweden
    Bioconjug Chem 7:584-91. 1996
  9. ncbi In vitro evaluation and biodistribution of HER2-targeted liposomes loaded with an (125)I-labelled DNA-intercalator
    A Fondell
    Department of Radiology, Oncology and Radiation Sciences, Unit of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Sweden
    J Drug Target 19:846-55. 2011
  10. ncbi Cellular processing of (125)I- and (111)in-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells
    A Orlova
    Department of Biomedical Radiation Sciences, Rudbecklaboratoriet, Uppsala University, Uppsala, Sweden
    Nucl Med Biol 27:827-35. 2000

Detail Information

Publications16

  1. ncbi Nuclisome--targeting the tumor cell nucleus
    Lars Gedda
    Department of Radiology, Oncology and Radiation Sciences, Unit of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, 751 85 Uppsala, Sweden
    Tumour Biol 33:661-7. 2012
    ..Results of in vitro and in vivo studies point towards the Nuclisome concept as a promising strategy for the treatment of small tumor masses and, in particular, for the elimination of spread single cells and micrometastases...
  2. ncbi Experimental radionuclide therapy of HER2-expressing xenografts using two-step targeting nuclisome particles
    Lars Gedda
    Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    J Nucl Med 53:480-7. 2012
    ..In the present study, the survival of mice intraperitoneally inoculated with human HER2-expressing SKOV-3 tumor cells and treated with HER2-targeting Nuclisome particles was studied...
  3. ncbi Cytotoxicity and subcellular localization of boronated phenanthridinium analogues
    L Gedda
    Department of Diagnostic Radiology, Uppsala University, Sweden
    Anticancer Drug Des 12:671-85. 1997
    ..The hypothesis is that the compounds are trapped in the cellular membranes of viable cells because of their lipophilicity, before reaching nuclear DNA...
  4. ncbi Real-time immunohistochemistry analysis of embedded tissue
    Lars Gedda
    Unit of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, SE 751 85 Uppsala, Sweden
    Appl Radiat Isot 68:2372-6. 2010
    ....
  5. ncbi The influence of lipophilicity on binding of boronated DNA-intercalating compounds in human glioma spheroids
    L Gedda
    Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Sweden
    Anticancer Drug Des 15:277-86. 2000
    ..The possibility of using these compounds for BNCT are discussed...
  6. ncbi Closo-dodecaborate(2-) as a linker for iodination of macromolecules. Aspects on conjugation chemistry and biodistribution
    V Tolmachev
    Division of Biomedical Radiation Sciences, Box 535, S 751 21, Uppsala University, Uppsala, Sweden
    Bioconjug Chem 10:338-45. 1999
    ..125I]Iodo-closo-dodecaborate(2-), which is a possible degradation product of [125I]Dx-BS-I, was rapidly excreted in urine without significant accumulation in any organ...
  7. ncbi Conjugate chemistry and cellular processing of EGF-dextran
    J Carlsson
    Unit of Biomedical Radiation Sciences, Uppsala University, Sweden
    Acta Oncol 38:313-21. 1999
    ..Different intracellular 'traffic routes' for the radionuclides are discussed as well as applications for both imaging and therapy...
  8. ncbi Development and in vitro studies of epidermal growth factor-dextran conjugates for boron neutron capture therapy
    L Gedda
    Department of Diagnostic Radiology, Uppsala University, Sweden
    Bioconjug Chem 7:584-91. 1996
    ..Theoretical calculations show that about 10(3) boron atoms per EGF-based conjugate are needed to give a satisfactory therapeutic response. These conjugates are within reach of that level...
  9. ncbi In vitro evaluation and biodistribution of HER2-targeted liposomes loaded with an (125)I-labelled DNA-intercalator
    A Fondell
    Department of Radiology, Oncology and Radiation Sciences, Unit of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Sweden
    J Drug Target 19:846-55. 2011
    ..Increasing attention is currently focussed on the issue of finding strategies for the delivery of Auger-electron-emitting radionuclides into tumor cell nuclei...
  10. ncbi Cellular processing of (125)I- and (111)in-labeled epidermal growth factor (EGF) bound to cultured A431 tumor cells
    A Orlova
    Department of Biomedical Radiation Sciences, Rudbecklaboratoriet, Uppsala University, Uppsala, Sweden
    Nucl Med Biol 27:827-35. 2000
    ..The use of nonphenolic linker did not improve retention of the radioactivity in A431 carcinoma cell line. The use of the radiometal label provided an appreciable prolongation of radioactivity residence inside the cell...
  11. ncbi Uptake of a boronated epidermal growth factor-dextran conjugate in CHO xenografts with and without human EGF-receptor expression
    P Olsson
    Department of Diagnostic Radiology, Uppsala, Sweden
    Anticancer Drug Des 13:279-89. 1998
    ..In conclusion, after intratumoral injections the conjugate showed receptor-dependent binding to EGFR-rich tumours, and the tumour-to-blood and tumour-to-liver ratios were promising...
  12. ncbi Astatinated trastuzumab, a putative agent for radionuclide immunotherapy of ErbB2-expressing tumours
    M I Persson
    Unit of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, S 751 85 Uppsala, Sweden
    Oncol Rep 15:673-80. 2006
    ..In conclusion, the results of the study suggest that astatinated trastuzumab is a promising candidate for treating ErbB2-expressing tumours...
  13. ncbi Effects of dextranation on the uptake of peptides in micrometastases: studies on binding of EGF in tumor spheroids
    P Nilsson
    Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    Tumour Biol 22:229-38. 2001
    ..The obtained differences could not be explained by differences in molecular weight or easily measured physicochemical parameters such as hydrophilic properties or isoelectric point values. Thus, other explanations must be found...
  14. ncbi Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin
    X Wu
    Unit of Oncology, Department of Oncology, Radiology and Clinical Immunology, Uppsala University, Uppsala, Sweden
    Br J Cancer 100:334-43. 2009
    ..Heat shock protein 90 represents a potential therapeutic target in the treatment of patients with oesophageal cancer, alone or in combination with radiotherapy...
  15. ncbi Planning for intracavitary anti-EGFR radionuclide therapy of gliomas. Literature review and data on EGFR expression
    J Carlsson
    Unit of Biomedical Radiation Sciences, Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
    J Neurooncol 77:33-45. 2006
    ..Instead, it is likely that the penetration properties of the targeting agents are critical, and detailed studies on this are urgent...
  16. ncbi Identification and characterization of a novel splicing variant of vesicular monoamine transporter 1
    M Essand
    Division of Clinical Immunology, Uppsala University, Sweden
    J Mol Endocrinol 35:489-501. 2005
    ..Furthermore, while VMAT1 can take up serotonin, VMAT1Delta15 cannot, indicating different functions for the two forms of VMAT1...